| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 45 | — | 17.3x | Around median | |
Growth | 31 | 5.5% | 7.1% | Bottom tier | |
Quality | 44 | -9.0% | 4.5% | Around median | |
Safety | 57 | 86.4x | 2.6x | Around median | |
Capital Return | 68 | 2.03% | 0.06% | Top tier | |
Momentum | 92 | 23.2% | -1.6% | Top tier | |
Sentiment | 63 | 16 | 3 | Around median |
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Gilead Sciences develops medicines to treat and prevent HIV and to treat liver diseases and cancer, generating revenue primarily from sales of these treatments. HIV remains its core business, with sales of 5.7 billion dollars in quarter 2 of fiscal year 2026 (ended 2026-06-30), compared with 877 million dollars for liver diseases, 457 million dollars for Trodelvy, and 417 million dollars for cell therapies. Its business model combines established products such as Biktarvy and Descovy, expanded indications for treatments such as Trodelvy, and the addition of long-acting options such as Yeztugo.
Revenue reached 7.8 billion dollars in quarter 2 of fiscal year 2026, with a gross margin of 79.8%, but the net loss reached 10.5 billion dollars, the operating margin was negative 133.2%, and the diluted loss per share was 8.45 dollars. These results coincided with acquired research and development charges related to the Arcellx, Tubulis, and Ouro Medicines transactions, making it necessary to distinguish product performance from the cost of expanding the portfolio to understand the results. A reliable comparison of year-over-year revenue growth or year-over-year margin changes is unavailable because the definition of the revenue line item differs between periods.
Despite the accounting loss, operating cash flow reached 3.6 billion dollars in quarter 2 of fiscal year 2026, according to EL7 data. Over the last 12 months through 2026-06-30, operating cash flow reached 13.6 billion dollars and free cash flow reached 13.0 billion dollars, according to EL7 data, compared with a net loss of 3.2 billion dollars. This cash-generating capacity provides the company with resources to fund drug development, but it is offset by total debt of 26.2 billion dollars and cash and short-term investments of 3.2 billion dollars at the end of quarter 2 of fiscal year 2026, according to EL7 data.
Q2 FY2026
Last 12 months to 2026-06-30
When: 2026-10-29
Gross margin compared with the 79.8% level at the expected earnings announcement
When: Fiscal year 2026
HIV sales growth within the guidance range of 9%–10%
The median target of 10 analysts is 161 dollars, within a range of 126–175 dollars, an estimate that incorporates growth expectations, while the discounted cash flow model value is 156 dollars, within a range of 122–212 dollars and at a discount rate of 8.7%, measuring the cash the business is expected to generate. The industry-multiple value is 141 dollars, within a range of 84–157 dollars, based on next year's earnings and a median multiple of 18.0 across 13 companies, measuring the company as its peers are valued. The median analyst target is closer to the cash flow estimate than either is to the industry-multiple value, and the difference reflects varying weights assigned to expected growth, cash generated, and relative peer pricing; analyst targets inherently tend toward optimism and cash flow models toward conservatism. In the data for the period ended 2026-06-30, EL7's valuation dimension, which measures relative valuation within the industry, ranks 45 out of 62 with a score of 29 out of 100.
Figures in the text are as of 2026-10-19; the live price is shown at the top of the page.
Gilead recorded a net loss of 10.5 billion dollars in quarter 2 of fiscal year 2026 (ended 2026-06-30), with an operating margin of negative 133.2%. The period's results were associated with acquired research and development charges related to Arcellx, Tubulis, and Ouro Medicines, so the loss alone does not measure demand for the medicines. Meanwhile, operating cash flow reached 3.6 billion dollars in the same quarter, according to EL7 data. The assessment of the transactions remains tied to their ability to turn assets under development into commercial products, including anito-cel and GS-8824.
Yeztugo targets HIV prevention with an injection every 6 months, while Biktarvy is a core treatment product. Yeztugo sales reached 232 million dollars in quarter 2 of fiscal year 2026 (ended 2026-06-30), up 40% compared with the previous quarter, with a target of approximately a billion dollars in fiscal year 2026. More than 70% of users returned for their injection after 6 months, according to data presented by management on the 2026-08-04 call. However, some switching to Yeztugo comes from the company's Descovy, so not every addition to its sales represents net new demand for Gilead's portfolio.
Automated analysis for informational purposes only — not investment advice.
Yeztugo sales compared with a target of approximately a billion dollars
HIV sales reached 5.7 billion dollars in quarter 2 of fiscal year 2026 (ended 2026-06-30), keeping this business at the center of revenue generation. Trodelvy sales reached 457 million dollars and Livdelzi sales reached 167 million dollars in the same quarter, with the former growing 26% and the latter exceeding twice the sales of the same quarter of the previous fiscal year. The Arcellx and Tubulis acquisitions added anito-cel and a platform for developing antibody-drug conjugates. These are specific steps toward diversification, but the expanding development pipeline has not yet translated into a balanced commercial distribution across the businesses.
Cell therapy sales declined 14% in quarter 2 of fiscal year 2026 (ended 2026-06-30) compared with the same quarter of the previous fiscal year to 417 million dollars because of competition. The Arcellx acquisition gave Gilead full ownership of anito-cel, with a regulatory decision date set for 2026-12-23 for fourth-line and later treatment of multiple myeloma. The company presented data showing a first-attempt manufacturing success rate of 98% and a global median turnaround time of 18 days. These figures support operational readiness, but they do not determine regulatory approval or post-approval sales volume.
The average analyst target is 153.13 dollars, while the median target is 161 dollars among 10 analysts, representing different measures of the distribution of expectations. The discounted cash flow estimate is 156 dollars, compared with 141 dollars using the industry multiple. These differences reflect what the methods measure: expected growth, cash generated, and valuation at peer multiples. Over the 90 days through 2026-10-19, 4 target increases and no reductions were recorded, including BofA Securities raising its target to 164 dollars on 2026-10-12.